Terms: = Colorectal cancer AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2
33 results:
1. The Role of Human Endogenous Retrovirus (HERV)-K119
Ko EJ; Kim MH; Kim DY; An H; Leem SH; Choi YH; Kim HS; Cha HJ
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958549
[TBL] [Abstract] [Full Text] [Related]
2. Mapping Immune Correlates and Surfaceome Genes in
Morafraile EC; Saiz-Ladera C; Nieto-Jiménez C; Győrffy B; Nagy A; Velasco G; Pérez-Segura P; Ocaña A
Curr Oncol; 2023 Feb; 30(3):2569-2581. PubMed ID: 36975409
[TBL] [Abstract] [Full Text] [Related]
3. Anti-colon cancer effects of Spirulina polysaccharide and its mechanism based on 3D models.
Lu Y; Chen Z; Lin Q; Xia X; Lin Y; Yan J; Huang M; Huang R
Int J Biol Macromol; 2023 Feb; 228():559-569. PubMed ID: 36581031
[TBL] [Abstract] [Full Text] [Related]
4. Anastomotic leakage following restorative rectal cancer resection: treatment and impact on stoma presence 1 year after surgery-a population-based study.
Eriksen JD; Emmertsen KJ; Madsen AH; Iversen LH
Int J Colorectal Dis; 2022 May; 37(5):1161-1172. PubMed ID: 35469107
[TBL] [Abstract] [Full Text] [Related]
5. Long-term Evaluation of Fistulotomy and Immediate Sphincteroplasty as a Treatment for Complex Anal Fistula.
Aguilar-Martínez MDM; Sánchez-Guillén L; Barber-Valles X; Alcaide-Quirós MJ; Bosch-Ramírez M; López-Delgado A; Tozer P; Arroyo A
Dis Colon Rectum; 2021 Nov; 64(11):1374-1384. PubMed ID: 34623349
[TBL] [Abstract] [Full Text] [Related]
6. Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience.
Pauly N; Baert T; Schmutzler R; du Bois A; Schneider S; Rhiem K; Schömig-Markiefka B; Siemanowski J; Heikaus S; Traut A; Heitz F; Prader S; Ehmann S; Harter P; Ataseven B
Arch Gynecol Obstet; 2021 Oct; 304(4):975-984. PubMed ID: 33710393
[TBL] [Abstract] [Full Text] [Related]
7. Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis.
Dabir PD; Bruggeling CE; van der Post RS; Dutilh BE; Hoogerbrugge N; Ligtenberg MJL; Boleij A; Nagtegaal ID
Eur J Hum Genet; 2020 Mar; 28(3):277-286. PubMed ID: 31695176
[TBL] [Abstract] [Full Text] [Related]
8. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by cd32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Caratelli S; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Pastore D; Cenciarelli C; Venditti A; Del Principe MI; Lauro D; Landoni E; Du H; Savoldo B; Ferrone S; Dotti G; Sconocchia G
Int J Cancer; 2020 Jan; 146(1):236-247. PubMed ID: 31479522
[TBL] [Abstract] [Full Text] [Related]
9. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
[TBL] [Abstract] [Full Text] [Related]
10. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma.
Park YY; An CH; Oh ST; Chang ED; Lee J
Medicine (Baltimore); 2019 Aug; 98(32):e16709. PubMed ID: 31393377
[TBL] [Abstract] [Full Text] [Related]
11. Socioeconomic differences in selection for liver resection in metastatic colorectal cancer and the impact on survival.
Vallance AE; van der Meulen J; Kuryba A; Braun M; Jayne DG; Hill J; Cameron IC; Walker K
Eur J Surg Oncol; 2018 Oct; 44(10):1588-1594. PubMed ID: 29895508
[TBL] [Abstract] [Full Text] [Related]
12. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in colorectal cancer.
Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
[TBL] [Abstract] [Full Text] [Related]
13. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract] [Full Text] [Related]
14. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic colorectal cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract] [Full Text] [Related]
16. Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II colorectal cancer: A Prospective Multicenter Trial.
Yamamoto H; Murata K; Fukunaga M; Ohnishi T; Noura S; Miyake Y; Kato T; Ohtsuka M; Nakamura Y; Takemasa I; Mizushima T; Ikeda M; Ohue M; Sekimoto M; Nezu R; Matsuura N; Monden M; Doki Y; Mori M
Clin Cancer Res; 2016 Jul; 22(13):3201-8. PubMed ID: 26831719
[TBL] [Abstract] [Full Text] [Related]
17. Patient characteristics associated with the level of patient-reported care coordination among male patients with colorectal cancer in the Veterans Affairs health care system.
Jackson GL; Zullig LL; Phelan SM; Provenzale D; Griffin JM; Clauser SB; Haggstrom DA; Jindal RM; van Ryn M
Cancer; 2015 Jul; 121(13):2207-13. PubMed ID: 25782082
[TBL] [Abstract] [Full Text] [Related]
18. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
Geva R; Vecchione L; Kalogeras KT; Jensen BV; Lenz HJ; Yoshino T; Paez D; Montagut C; Souglakos J; Cappuzzo F; Cervantes A; Frattini M; Fountzilas G; Johansen JS; Høgdall EV; Zhang W; Yang D; Yamazaki K; Nishina T; Papamichael D; Vincenzi B; Macarulla T; Loupakis F; De Schutter J; Spindler KL; Pfeiffer P; Ciardiello F; Piessevaux H; Tejpar S
Gut; 2015 Jun; 64(6):921-8. PubMed ID: 25011934
[TBL] [Abstract] [Full Text] [Related]
19. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
Muallaoglu S; Disel U; Mertsoylu H; Besen A; Karadeniz C; Taner Sumbul A; Abali H; Ozyilkan O
J BUON; 2013; 18(1):261-7. PubMed ID: 23613414
[TBL] [Abstract] [Full Text] [Related]
20. The anthocyanin metabolites gallic acid, 3-O-methylgallic acid, and 2,4,6-trihydroxybenzaldehyde decrease human colon cancer cell viability by regulating pro-oncogenic signals.
Forester SC; Choy YY; Waterhouse AL; Oteiza PI
Mol Carcinog; 2014 Jun; 53(6):432-9. PubMed ID: 23124926
[TBL] [Abstract] [Full Text] [Related]
[Next]
